Expert Opinion on Pharmacotherapy

Article	Citations
Pharmacotherapy developments in autophagy inhibitors for bladder cancer	40
Antidepressant medications in women aged 40 and older and the risk of fragility fractures: a systematic literature review and meta-analysis	39
The pharmacological treatment and management of hyperhidrosis	38
Promising therapies for adults with symptomatic obstructive hypertrophic cardiomyopathy: 2023 and beyond	36
Oral anticoagulation therapy in the setting of liver disease	35
Perspectives on the advances in the pharmacotherapeutic management of Duchenne muscular dystrophy	35
A 2023 update on the advancements in the treatment of agitation in Alzheimer’s disease	34
Current treatment options for Mycobacterium marinum cutaneous infections	32
Real-world safety and effectiveness of roxadustat in patients with anemia of chronic kidney disease: interim results from a post-marketing surveillance study in Japan	29
Advances in the management of obstructive hypertrophic cardiomyopathy: The role of mavacamten	28
Evaluating the safety and efficacy of seladelpar for adults with primary biliary cholangitis	25
Chemotherapy in resectable or potentially resectable colon cancer with liver metastases	24
Efficacy of 3-day versus 5-day aprepitant regimens for long-delayed chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy	24
Rheumatoid arthritis in Latin America: pharmacotherapy and clinical challenges	24
An overview of mineralocorticoid receptor antagonists as a treatment option for patients with heart failure: the current state-of-the-art and future outlook	23
Comprehensive overview of the available pharmacotherapy for the treatment of non-neurogenic overactive bladder in children	22
How useful is chemotherapy for atypical and anaplastic meningiomas?	21
GnRH agonists and antagonists in therapy of symptomatic uterine fibroids – current roles and future perspectives	21
Pharmacotherapeutic options in pediatric obesity: an urgent call for further research	20
Current and emerging pharmacotherapies for the treatment of pulmonary arterial hypertension in infants	20
An evaluation of ivosidenib for the treatment of IDH1-mutant cholangiocarcinoma	19
Efficacy and safety of G-CSF prophylaxis in patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy	19
An up-to-date overview of the pharmacotherapeutic options for premature ejaculation	18
Pharmacotherapy of persistent genital arousal disorder/genito-pelvic dysesthesia: an updated review and data from a registry	18
A systematic review of economic evaluations of tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC)	18

Pharmacotherapy for CD55 deficiency with CHAPLE disease: how close are we to a cure?	17
When is pharmacotherapy necessary for the treatment of seasonal affective disorder?	17
Correction	16
Momelotinib in myelofibrosis	16
Selecting optimal therapy in systemic mastocytosis: current state and future directions	16
Zanubrutinib for the treatment of chronic lymphocytic leukemia	15
Rise and fall of decongestants in treating nasal congestion related diseases	15
Association between clinical and laboratory factors and response to sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes: a retrospective observational study	15
Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapy	15
Benefits and disadvantages of combination therapy with imeglimin and metformin in patients with type 2 diabetes	15
Approved medications for opioid use disorder : current update	15
Potential treatments for attention-deficit/hyperactivity disorder: a focus on Phase III trials	15
Resmetirom: the first approved therapy for treating metabolic dysfunction associated steatohepatitis	15
Pharmacotherapy of treatment-resistant hypertension in patients with chronic kidney disease	15
Pharmacologic management of ET: established therapies and emerging agents	15
Metabolic dysfunction-associated steatohepatitis treatment: spotlight on the latest hepatoprotective drugs	14
An update on the considerations for patients with rheumatic disease being treated with rituximab during the COVID-19 pandemic and the potential drug treatment strategies	14
Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature	14
Correction	14
The role of the D3 dopamine receptor and its partial agonist cariprazine in patients with schizophrenia and substance use disorder	14
Looking ahead to potential incretin combination therapies for nonalcoholic steatohepatitis in patients with diabetes	14
Evaluating pimavanserin tartrate as a treatment in Parkinson’s disease	13
Tirzepatide for overweight and obesity management	13
Pharmacotherapy considerations in patients who develop acute kidney injury during anti-cancer therapy	13
Long-acting second-generation injectable antipsychotics for the maintenance treatment of bipolar disorder: a narrative review	13
Advances in adrenergic receptors for the treatment of chronic obstructive pulmonary disease: 2023 update	13
Effectiveness and safety of oral terbinafine for dermatophyte distal subungual onychomycosis	13
Current pharmacological solutions for Behçet’s syndrome	13
Current advancements in pharmacotherapy for cancer cachexia	12
Current pharmacotherapeutic strategies for Strongyloidiasis and the complications in its treatment	12
Pharmacogenomics and pediatric drug development: science and political power. A narrative review	12
Treating pediatric aggressive behaviors and comorbid conditions	12
An evaluation of the pharmacotherapeutic options for the treatment of adult phimosis. A systematic review of the evidence	12
Use of glucagon-like polypeptide 2 analogs for intestinal failure	12
An update on current pharmacotherapy for vulvar cancer	12
Upadacitinib in Crohn’s disease	12
Updates in pharmacotherapy for non-small cell lung cancer: a focus on emerging tubulin inhibitors	12
What is the impact of catechol-O-methyltransferase (COMT) on Parkinson’s disease treatment?	12
Drug treatment strategies for eosinophilic esophagitis in adults	11
Optimizing drug therapy for older adults: shifting away from problematic polypharmacy	11
Efficacy and tolerability of desvenlafaxine in the real-world treatment of patients with major depression: a narrative review and an expert opinion paper	11
Current and emerging pharmacotherapy for the management of hypertrophic cardiomyopathy	11
Pharmacotherapy for cervical cancer: current standard of care and new perspectives	11
Current and emerging COX inhibitors for treating postoperative pain following oral surgery	11
Recent advances in Alzheimer’s disease therapy: clinical trials and literature review of novel enzyme inhibitors targeting amyloid precursor protein	11
Simnotrelvir as a potential treatment for COVID-19	11
Tackling pulmonary fibrosis risks in post-COVID-19: cutting-edge treatments	11
Recent progress in the use of pharmacotherapy for endometrial cancer	11
Advances with androgen deprivation therapy for prostate cancer	11
Pharmacotherapeutic strategies for the treatment of anorexia nervosa – novel targets to break a vicious cycle	11

The role of sulfonylureas in the treatment of type 2 diabetes	10
Revolutionizing hepatitis C treatment: next-gen direct-acting antivirals	10
Pharmacotherapy for Gastrointestinal Angiodysplasia: is it effective?	10
Update on novel antipsychotics and pharmacological strategies for treatment-resistant schizophrenia	10
Evaluation of prescribing patterns of switching to and add-on lemborexant in patients treated with hypnotic medication: a nationwide claims database study in Japan	10
Pharmacological management of pituitary adenomas – what is new on the horizon?	10
Pharmaceutical advances in the treatment of gastric adenocarcinoma	10
Evidence-based prescribing of medications for ADHD: where are we in 2023?	10
Modern pharmacotherapy guidance for treating alcohol use disorders	10
Response to the letter to the editor: ‘Olezarsen, a liver-directed APOC3 ASO therapy for hypertriglyceridemia’	10
An evaluation of pharmacological options for Cushing’s disease: what are the state-of-the-art options?	10
Melanoma and pediatric drug development: clinical progress vs. regulatory activism in minors - a narrative review	9
New antibiofilm strategies for the management of nontuberculous mycobacteria diseases	9
A comparison of front-line oral anticoagulants for the treatment of non-valvular atrial fibrillation: effectiveness and safety of direct oral anticoagulants in the FANTASIIA registry	9
An overview of emergency pharmacotherapy for priapism	9
Evaluating fostamatinib disodium as a treatment option for immune thrombocytopenia in adult patients	9
Current and emerging pharmacotherapies in Lennox-Gastaut syndrome	9
Reassessing the role of aspirin in patients with coronary artery disease	9
Perspectives on the current pharmacological strategies for chronic and atrophic gastritis: can more be done?	9
Migraine in multiple sclerosis patients: potential links and treatment approach	9
Evaluating the safety and efficacy of baricitinib for the treatment of moderate-to-severe atopic dermatitis	9
Elinzanetant, a new combined neurokinin-1/-3 receptor antagonist for the treatment of postmenopausal vasomotor symptoms	9
Advances in the pharmacotherapeutic management of refractory peptic ulcers	9
Pharmacological management of gastro-esophageal reflux disease: state of the art in 2024	9
Current status of intracavernosal injection therapy in erectile dysfunction	9
An update on the currently available and emerging synthetic pharmacotherapy for uncontrolled asthma	9
Recent advances in the pharmacotherapeutic management of diabetic kidney disease	9
Pharmacological management of digital ulcers in systemic sclerosis - what is new?	9
Evaluating obicetrapib as an emerging treatment for patients with dyslipidemia: a game changer?	9
Amyloidosis of the heart: pathophysiology, diagnosis, and treatment	8
Risk management of medication errors: a novel conceptual framework	8
An update on antifungal resistance in dermatophytosis	8
Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today?	8
Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis	8
Optimizing the management of patients with worsening heart failure: beyond heart failure hospitalization	8
A comprehensive update on the pharmacological management of heterotopic ossification following hip arthroplasty: a level I evidenced based expert opinion	8
Canagliflozin + metformin ER for the treatment of type 2 diabetes: the evidence to date	8
Longitudinal efficacy of Ertugliflozin in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials	8
The management of cardiovascular disease risk in patients with rheumatoid arthritis	8
Clinical, metabolic, and immune interaction between tuberculosis and diabetes mellitus: implications and opportunities for therapies	8
Clinical guidance for choosing the right pharmacotherapy for migraine attacks	8
Cutting-edge pharmacotherapy for hepatitis C virus infection: a comprehensive review	8
Is there a pathway for phosphatidylinositol 3-kinase delta inhibitors to be approved therapeutics for B-cell lymphoma therapy	8
Evaluating upadacitinib for the treatment of psoriatic arthritis	8
The impact of age, disease severity, and vaccination status on antibiotic use in hospitalized patients with COVID-19	8
An update on the pharmacological management of acne vulgaris: the state of the art	8
Addressing the long-term risks of administering antenatal steroids	8
Pharmacological and behavioral pain treatment strategies for patients with opioid use disorder	8
A review of pharmacokinetic data describing long-acting injectable cabotegravir during pregnancy	8
Pharmacological management of fragile X syndrome: a systematic review and narrative summary of the current evidence	8
Current and emerging pharmacotherapy for respiratory syncytial virus (RSV) infection in infants	8
Effective risk reduction strategies and pharmacological treatment for uncomplicated recurrent urinary tract infections	8
Pharmacological management of migraine: current strategies and future directions	8
Update on current and emerging treatment paradigms for hyperphosphatemia in chronic kidney disease	8
Current and emerging tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia in young adults	8
Profile of tirzepatide in the management of type 2 diabetes mellitus: design, development, and place in therapy	8
Will elinzanetant, a neurokinin receptor antagonist, have a role in the treatment of hot flashes?	8
An update on the pharmacotherapy of gout	8
Recently approved and emerging drug options for migraine prophylaxis	8
Using sequential pharmacotherapy for the treatment of osteoporosis: an update of the literature	8
Pharmacological treatment for children with constipation: present and future	8
Time to reconsider the way of selecting antihypertensives for hypertensive left ventricular hypertrophy	8
Levodopa-induced dyskinesia: do current clinical trials hold hope for future treatment?	7
Novel pharmacotherapies and breakthroughs in psoriasis treatment: 2024 and beyond	7
Recent updates in the use of pharmacological therapies for downstaging in patients with hepatocellular carcinoma	7
Navigating the liver landscape: upcoming pharmacotherapies for primary sclerosing cholangitis	7
Guidance for the pharmacological management of COVID-19 in the emergency setting	7
An evaluation of sebetralstat as the first oral on-demand therapy for Hereditary Angioedema	7
Current and emerging drug strategies for the prevention of venous thromboembolism in acutely ill medical inpatients	7
Advances in the pharmacological management of acute myeloid leukemia in adults	7
Improving the pharmacotherapeutic treatment of agitation associated with bipolar disorder	7
Glasdegib for the treatment of acute myeloid leukemia	7
Metabolic-associated steatotic liver disease and hepatocellular carcinoma	7
A large-scale database study for the prescription status of a new voltage-gated Ca2+ channel α2δ ligand, mirogabalin, in Japan	7
A systematic review on effect of sodium-glucose cotransporter-2 inhibitors on the metabolic and endocrinological profile of patients with polycystic ovarian syndrome	7
State-of-the-art and emerging antivirals for chronic hepatitis B infection	7
Current pharmacological strategies for symptomatic reduction of persistent breathlessness – a literature review	7
Clinical direction in the pharmacological and device management of refractory overactive bladder: the urge to develop new treatments	7
The pharmacological management of treatment-resistant depression: what does the future hold?	7
Identifying the challenges for successful pharmacotherapeutic management of sarcopenia	7

Upadacitinib in Crohn’s disease: needs more insight	7
Advances in non-hormonal pharmacotherapy for the treatment of male infertility: the role of inositols	7
Combining finerenone with SGLT-2 inhibitors: building up CONFIDENCE for the treatment of diabetic kidney disease	7
The pharmacological management of alcohol-related cirrhosis: what’s new?	7
The evolving atopic dermatitis management landscape	7
Making a prescribing choice for rheumatoid arthritis: a focus on small molecule drugs vs. biologics for the most favourable patient outcome	7
Impact of bladder cancer family history on the prognosis of patients with non-muscle invasive bladder cancer treated with Bacillus Calmette-Guerin (BCG)	7
New and emerging drugs for the treatment of invasive fungal infections	7
Advice and challenges in the pharmacotherapeutic management of diabetic kidney disease in adults	7
Promising therapies for the treatment of acromegaly	7
Advances in pharmacotherapy for bronchiectasis in adults	7
Pharmacotherapy in leishmaniasis: old, new treatments, their impacts and expert opinion	7
Montelukast as a potential treatment for COVID-19	6
A Systematic Review on Safety and Efficacy of Migalastat for the treatment of Fabry’s Disease	6
Expert guidance for treating anemia in chronic kidney disease: what is the appropriate drug treatment strategy?	6
What are the pharmacotherapeutic considerations for the treatment of myasthenia gravis?	6
An overview of the current drug treatment strategies for moderate to severe, chronic malignant tumor-related pain	6
Current factor IX replacement options for hemophilia B and the challenges ahead	6
Pharmacological management of heart failure: a patient-centred approach	6
GLP-1 receptor agonists in the treatment of diabetic non–alcoholic steatohepatitis patients	6
Pharmacotherapy for bipolar disorder in adults with high-functioning autism	6
Clinical challenges and considerations in pharmacotherapy of osteoporosis due to menopause	6
Novel pharmacotherapy for drug-induced immune hemolytic anemia	6
A systematic review of the effect of semaglutide on lean mass: insights from clinical trials	6
Paxlovid as a potential treatment for long COVID	6
Pharmacotherapeutic strategies for hepatitis B and hepatitis C coinfection	6
Advances in pharmacotherapy for cholangiocarcinoma: from conventional therapies to targeted drugs	6
An update on inclisiran for the treatment of elevated LDL cholesterol	6
Systemic approaches in biliary tract cancers: a review in the era of multidirectional precision medicine	6
Current and emerging pharmacotherapy for the treatment of Lennox-Gastaut syndrome	6
How far are we from an approved drug for nonalcoholic steatohepatitis?	6
Pharmacotherapy for the treatment of recurrent cervical cancer: an update of the literature	6
FGFR inhibitor resistance in cholangiocarcinoma: current understanding and future directions	6
Streptozotocin in pancreatic neuroendocrine tumors: a focus on efficacy and safety	6
Evaluating posaconazole, its pharmacology, efficacy and safety for the prophylaxis and treatment of fungal infections	6
The first five years of SARS-CoV-2: inpatient treatment updates and future directions	6
Moving from serotonin to serotonin-norepinephrine enhancement with increasing venlafaxine dose: clinical implications and strategies for a successful outcome in major depressive disorder	6
The current state-of-the-art in pharmacotherapy for pulmonary sarcoidosis	6
Evaluating 5 alpha reductase inhibitors for the treatment of male androgenic alopecia	6
Factor VIII stimulants and other novel therapies for the treatment of von Willebrand disease: what’s new on the horizon?	6
Pharmacological management of connective tissue disease-associated pulmonary arterial hypertension	6
Does standard pharmacotherapy still have a major role in the treatment of aggressive B-cell malignancies?	6
Liposomal drug formulations for treatment of hematological malignancies	6
Combination intravesical chemotherapy for non-muscle invasive bladder cancer (NMIBC) as first-line or rescue therapy: where do we stand now?	6
Venetoclax and new BCL-2 inhibitors in acute myeloid leukemia	6
Pharmacotherapy for gastric and intestinal cramping pain: ‎ current and emerging therapies	6
Polypharmacology of carbonic anhydrase inhibitors and activators	6
Cardio-reno-vascular protection in type 2 diabetes mellitus: new insights into pharmacotherapeutic management	6
An evaluation of aumolertinib for the treatment of EGFR T790M mutation-positive non-small cell lung cancer	6